BIOVAIL LAUNCHES GLUMETZA TO CANADIAN PHYSICIANS
Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has officially launched GlumetzaTM in Canada. Developed in partnership with Depomed, Inc. (NASDAQ:DEPO) of Menlo Park, California, GlumetzaTM is the first once-daily, extended-release formulation of metformin on the Canadian market. GlumetzaTM is being launched by Biovail Pharmaceuticals Canada (BPC), the Canadian sales and marketing division of Biovail Corporation. This launch further validates BPC's position as the number-one independent pharmaceutical commercial organization in the country.